The stock of KemPharm Inc (NASDAQ:KMPH) closed at $6.55 losing 3.68% in yesterday’s trading session. KemPharm, Inc has moved ahead to unleash its fourth quarter and year end corporate and financial results. The results were for the full year ended December 31, 2017 and official working with the company has said that there are a lot of lessons to be learned.
The President and Chief Executive Officer of KemPharm Travis C. Mickle has moved ahead to say that the past few months have been transformational for them as a company. It has been around the same period of time that FDA proceeded to give its approval for APADAZ.
This is a product that helps a huge deal in the treatment of patients experiencing the acute sort of pain. KP415, the company’s lead ADHD prodrug product candidate might soon be taking over the markets enabling the company scale higher in terms of rankings.
There has been a lot of activity recently but the one thing worth noting is the fact that the company is mobilizing its efforts and resources towards ensuring that it avails working solutions to its wide customer base. The difficult to treat conditions according to market observers have subjected a lot of people to much suffering.If all moves according to plan, the products of this business giant will be moving quite a long way in solving the puzzle.
A top executive working with KemPharm, Inc after attending a business conference that was held recently addressed several journalists. He outlined that there were a lot of advancements across their company’s pipeline and that was sufficient proof that the company’s team was dedicate to progress.
This company’s LAT™ (Ligand Activated Therapy) prodrug platform is one of a kind and most of the good news moving around about the company is in one way or the other tied to it. In one way or the other, it is expected that 2018 will be one of the highest notches for a company whose dreams have always been to deliver the very best in terms of health care at the most affordable rates.